- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00227500
Pravastatin for Hyperlipidaemia in HIV.
A Randomised, Double-Blind Study of Pravastatin for the Treatment of Hyperlipidaemia in Patients With HIV
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
High serum cholesterol concentrations are commonly seen in HIV-infected patients treated with some protease inhibitor medications as part of long-term antiretroviral therapy for HIV. There is concern that these elevations in cholesterol may negatively impact on long-term risk of cardiovascular disease in this patient population. Pravastatin, a HMG-CoA reductase inhibitor, is commonly used to treat hypercholesterolaemia in the general population. We aim to examine the effect of 12 weeks therapy with 40mg pravastatin daily in conjunction with dietary advice in HIV-infected patients with elevated serum cholesterol on continued protease inhibitor therapy.
After 4 weeks of dietary advice, patients will be randomised to receive either pravastatin or placebo for 12 weeks. Assessments include fasting lipid and glycaemic parameters, measures of body composition and HIV disease, and surrogate markers for cardiovascular disease.
Although previous small studies of pravastatin in this field have been performed, none has done so in a randomised placebo controlled trial taking into account all the relevant measures.
Study Type
Enrollment
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
New South Wales
-
Sydney, New South Wales, Australia, 2010
- St. Vincents Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Provide written informed consent to participate in the trial
- HIV-1 sero-positive
- Male/female >18 years age
- Currently receiving HIV protease inhibitor therapy for > 12 weeks and unlikely to require change in existing regimen during the 16 week study period
- Fasting cholesterol > 6.5 mmol/L (mean of 2 samples collected > 3 days apart)
Exclusion Criteria:
- Any condition which may interfere with ability to comply with study
- Gastrointestinal disorder which may affect drug absorption
- Hypertension or congestive cardiac failure
- Lactic acidemia (serum lactate level >2.2 mmol/L)
- Any serious medical condition which may compromise the patient's safety, including pancreatitis or hepatitis within past 6 months
- Active AIDS defining conditions
- Concurrent therapy with any other lipid lowering agents, oral hypoglycaemics, anabolic steroids or insulin
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Between-group difference in time weighted change from baseline in fasting serum total cholesterol
|
Secondary Outcome Measures
Outcome Measure |
---|
Includes: between-group difference in time weighted change: from wk 4 in fasting serum total cholesterol as well as from baseline in HDL-cholesterol and triglycerides; in total and regional body fat; in endothelial function
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Andrew D Carr, MD, National Centre in HIV Epidemiology and Clinical Research.
- Study Director: David A Cooper, MD, National Centre in HIV Epidemiology and Clinical Research.
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Metabolic Diseases
- Skin Diseases
- Lipid Metabolism Disorders
- Dyslipidemias
- Skin Diseases, Metabolic
- Cardiovascular Diseases
- Hyperlipidemias
- Lipodystrophy
- Hyperlipoproteinemias
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites
- Anticholesteremic Agents
- Hypolipidemic Agents
- Lipid Regulating Agents
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Pravastatin
Other Study ID Numbers
- PRAVA
- PRAVA / RO1 HL65953-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedHIV Infections | HIV SeronegativityUnited States, Puerto Rico
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
Clinical Trials on Pravastatin
-
Akros Pharma Inc.CompletedType II HyperlipidemiaNetherlands
-
Daiichi Sankyo, Inc.CompletedHypercholesterolemiaUnited States
-
Pontificia Universidad Catolica de ChileBristol-Myers SquibbWithdrawn
-
National Center for Research Resources (NCRR)UnknownHeart DiseasesUnited States
-
Yonsei UniversityCompleted
-
University of Colorado, DenverNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedPolycystic Kidney, Autosomal DominantUnited States
-
Arkansas Children's Hospital Research InstituteTerminatedEnd Stage Renal DiseaseUnited States
-
Bristol-Myers SquibbCompletedActue Coronary Syndromes
-
Mitsukoshi Health and Welfare FoundationDaiichi Sankyo Co., Ltd.; Ministry of Health, Labour and Welfare, JapanCompleted
-
Gachon University Gil Medical CenterCompleted